Clinical Trials
58 trialsVABu Conditioning in Elderly AML HSCT
The First Affiliated Hospital of Soochow University
REVIVAL
AbbVie
COSI
University of Birmingham
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
FIT-AML
European Organisation for Research and Treatment of Cancer - EORTC
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
National Cancer Institute (NCI)
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
WT1 for the Detection of Minimal Residual Disease
Ann & Robert H Lurie Children's Hospital of Chicago
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
BIG-1
University Hospital, Angers
Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors
Seoul St. Mary's Hospital
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
ALFA1401
Versailles Hospital
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
THRIVE
Bellicum Pharmaceuticals
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
Basilea Pharmaceutica
VHA
The First Affiliated Hospital of Soochow University
GLOBAL
Gruppo Italiano Trapianto di Midollo Osseo
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
The First Affiliated Hospital of Soochow University
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Peking University People's Hospital
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Nanfang Hospital, Southern Medical University
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
SPARK-AML1
AstraZeneca
AML18
Cardiff University
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
Fujian Medical University
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Nanfang Hospital, Southern Medical University
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
Janssen Research & Development, LLC
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
Nanfang Hospital, Southern Medical University
Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML
Nanfang Hospital, Southern Medical University
Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML
Nanfang Hospital, Southern Medical University
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
University of Ulm
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
ExCell
Gamida Cell -Teva Joint Venture Ltd.
DeGREE
Seoul St. Mary's Hospital
MYFLAI07
University Hospital, Udine, Italy
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation
National Cancer Institute (NCI)